Two landmark developments last week expose the inner machinery of an American health complex that erects legal walls around institutional power while leaving the public exposed to compounding harms. The first struck from the Department of Health and Human Services (HHS), which formally announced the termination of the COVID-19 Emergency Use Authorization (EUA) declarations that have underpinned the federal pandemic response since early 2020. The second came from the Supreme Court, which ruled 7–2 in 'Monsanto Co. v. Durnell' that federal pesticide law preempts state “failure-to-warn” lawsuits, a decision widely expected to derail thousands of claims from Americans who developed non-Hodgkin lymphoma after chronic Roundup exposure.
HHS announced determinations ending the EUA framework for drugs, biologics, and medical devices, establishing transition periods of twelve months and 180 days respectively. These declarations formed the legal foundation for the authorization of mRNA injections, monoclonal antibodies, antiviral drugs, ventilators, diagnostic tests, and personal protective equipment. Yet the termination is largely symbolic. Because the Pfizer and Moderna mRNA products have already secured full FDA approval, dismantling the emergency structure does not remove them from circulation or shield Americans from products that rolled out under the liability protections the EUA once afforded their manufacturers. The complex has completed the regulatory alchemy it needed: emergency authorities served as the bridge to permanent licensing, and now the scaffolding can be ceremonially discarded while the pharmaceutical apparatus it constructed remains fixed in place, its products neither recalled nor subjected to independent long-term re-evaluation.
Across the regulatory landscape, the Supreme Court similarly prioritized corporate immunity over human health. By holding that pesticide companies cannot be sued under state law for omitting cancer warnings the EPA never required, the justices insulated Monsanto from accountability for glyphosate exposure. The ruling ignores a growing body of peer-reviewed scientific evidence—including a 2019 meta-analysis by Zhang et al. pooling data from over 65,000 participants that found a 41% increased risk of non-Hodgkin lymphoma among those with the highest glyphosate exposure. It also ignores a now-retracted 2000 “safety” review that *Regulatory Toxicology and Pharmacology* formally withdrew in late 2025 after investigators confirmed it was ghostwritten by Monsanto employees who concealed carcinogenicity data, fabricated independent authorship, and buried financial conflicts of interest. With glyphosate already detected in the bodies of more than 80% of Americans, the Court has effectively enshrined fraudulent science into legal precedent, preventing the poisoned from seeking redress.
Nicolas Hulscher, who joined the Heartland Journal podcast as a guest to examine these intersecting crises, argues that the pattern spanning both pharmaceutical and agrochemical policy is unmistakable. Whether the mechanism is a pandemic-era emergency decree that outlives its stated public health mission or a judicial shield that locks a retracted corporate study into binding law, the American health complex operates by the same design: it protects its architects while transferring risk to the population. Until Congress and regulators strip away—not merely rebrand—the emergency powers, preemption doctrines, and liability shields that corporations have learned to weaponize, citizens will remain the unconsenting subjects of ongoing experiments, and the industries that profit from exposure will stay legally untouchable.
